Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma
Dai Ogata(University of Miyazaki), Tetsuya Tsuchida(Saitama Medical University), Naoya Yamazaki, Kohei Oashi(Saitama Cancer Center), Kenji Suzuki(Saitama Medical University), Hiroto Yanagisawa(Saitama Medical University)
Cited by 39
Related Papers
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
|Oncotarget|2016|160
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
|Annals of Oncology|2020|140